HC Wainwright Brokers Boost Earnings Estimates for Alkermes

Key Points

• HC Wainwright raised its Q3 2025 earnings estimate for Alkermes to $0.31 per share, a modest increase from the previous estimate of $0.30.
• Alkermes reported earnings of $0.52 EPS for the last quarter, exceeding expectations of $0.42 EPS, while revenue reached $390.66 million compared to forecasts of $343.20 million.
• Current analyst ratings show a consensus of "Moderate Buy" with an average price target of $41.08, featuring nine buy ratings and one strong buy rating.

Alkermes plc (NASDAQ:ALKS - Free Report) - HC Wainwright increased their Q3 2025 earnings estimates for shares of Alkermes in a research report issued on Wednesday, July 30th. HC Wainwright analyst D. Tsao now expects that the company will earn $0.31 per share for the quarter, up from their prior forecast of $0.30. HC Wainwright has a "Neutral" rating and a $46.00 price target on the stock. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. HC Wainwright also issued estimates for Alkermes' Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.47 EPS, Q2 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.39 EPS and FY2026 earnings at $1.22 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.42 by $0.10. The firm had revenue of $390.66 million during the quarter, compared to the consensus estimate of $343.20 million. Alkermes had a return on equity of 24.86% and a net margin of 23.15%. The business's quarterly revenue was down 2.1% on a year-over-year basis. During the same period last year, the company earned $1.16 earnings per share.

Several other equities analysts also recently commented on ALKS. The Goldman Sachs Group assumed coverage on Alkermes in a research report on Tuesday, July 15th. They issued a "buy" rating and a $43.00 target price for the company. Wall Street Zen cut Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. Royal Bank Of Canada increased their price target on Alkermes from $40.00 to $42.00 and gave the company a "sector perform" rating in a research note on Wednesday, July 30th. Needham & Company LLC reissued a "buy" rating and issued a $45.00 price target on shares of Alkermes in a research note on Tuesday, July 29th. Finally, Cantor Fitzgerald raised Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Alkermes presently has a consensus rating of "Moderate Buy" and an average price target of $41.08.

Alkermes Trading Up 0.2%

Alkermes stock opened at $26.55 on Monday. The company has a market capitalization of $4.38 billion, a PE ratio of 12.76, a P/E/G ratio of 1.52 and a beta of 0.47. Alkermes has a 12 month low of $25.56 and a 12 month high of $36.45. The stock has a 50-day moving average price of $29.21 and a two-hundred day moving average price of $30.78.

Institutional Investors Weigh In On Alkermes

Several institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in Alkermes by 147.4% in the 4th quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company's stock valued at $25,581,000 after buying an additional 529,962 shares in the last quarter. Ritholtz Wealth Management bought a new stake in Alkermes in the 1st quarter valued at about $348,000. Victory Capital Management Inc. increased its position in Alkermes by 30.9% in the 1st quarter. Victory Capital Management Inc. now owns 120,997 shares of the company's stock valued at $3,995,000 after buying an additional 28,596 shares in the last quarter. GAMMA Investing LLC increased its position in Alkermes by 31.9% in the 1st quarter. GAMMA Investing LLC now owns 5,396 shares of the company's stock valued at $178,000 after buying an additional 1,305 shares in the last quarter. Finally, Captrust Financial Advisors increased its position in Alkermes by 9.7% in the 4th quarter. Captrust Financial Advisors now owns 18,362 shares of the company's stock valued at $528,000 after buying an additional 1,619 shares in the last quarter. Institutional investors own 95.21% of the company's stock.

Insider Activity at Alkermes

In related news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the sale, the senior vice president owned 86,208 shares in the company, valued at $2,680,206.72. This represents a 3.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.40% of the stock is currently owned by insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.